Medicine

AD04-13 Study Highlights Consistent Bioavailability and Safety for Alcohol Use Disorder Treatment

January 20, 2025 - By 

Cary Claiborne, CEO, Adial Pharmaceuticals, discusses promising results of the AD04-13 study in patients with Alcohol Use Disorder

Related Posts

FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk

February 19, 2025

Navigating Distrust: Pharma in the Age of Social Media

February 19, 2025

Pharmaceutical Executive: February 2025 Issue (PDF)

February 18, 2025

Leave a Reply

Your email address will not be published. Required fields are marked *